CoChat

The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder

Open access
Fountoulakis, Konstantinos N, Yatham, Lakshmi N, Grunze, Heinz, Vieta, Eduard, Young, Allan H, Blier, Pierre, Tohen, Mauricio, Kasper, Siegfried, Moeller, Hans Jurgen · 2020 · International Journal of Neuropsychopharmacology
Cited by 77

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Abstract

Background: Resistant bipolar disorder is a major mental health problem related to significant disability and overall cost. The aim of the current study was to perform a systematic review of the literature concerning (1) the definition of treatment resistance in bipolar disorder, (2) its clinical and (3) neurobiological correlates, and (4) the evidence-based treatment options for treatment-resistant bipolar disorder and for eventually developing guidelines for the treatment of this condition Materials and Methods: The PRISMA method was used to identify all published papers relevant to the definition of treatment resistance in bipolar disorder and the associated evidence-based treatment options. The MEDLINE was searched to April 22, 2018. Results: Criteria were developed for the identification of resistance in bipolar disorder concerning all phases. The search of the literature identified all published studies concerning treatment options. The data were classified according to strength, and separate guidelines regarding resistant acute mania, acute bipolar depression, and the maintenance phase were developed. Discussion: The definition of resistance in bipolar disorder is by itself difficult due to the complexity of the clinical picture, course, and treatment options. The current guidelines are the first, to our knowledge, developed specifically for the treatment of resistant bipolar disorder patients, and they also include an operationalized definition of treatment resistance. They were based on a thorough and deep search of the literature and utilize as much as possible an evidence-based approach.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ijnp/pyz064

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Research works printed but not linked: 282

  1. Abdallah, 2012, Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting, J ECT, 28, 157, 10.1097/YCT.0b013e31824f8296 · DOI
  2. Altshuler, 1999, Gabapentin in the acute treatment of refractory bipolar disorder, Bipolar Disord, 1, 61, 10.1034/j.1399-5618.1999.10113.x · DOI · Paper page
  3. Altshuler, 2009, Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study, J Clin Psychiatry, 70, 450, 10.4088/JCP.08m04191 · DOI · Paper page
  4. Amann, 2007, A 2-year, open-label pilot study of adjunctive chromium in patients with treatment-resistant rapid-cycling bipolar disorder, J Clin Psychopharmacol, 27, 104, 10.1097/JCP.0b013e31802e744b · doi:10.1097/jcp.0b013e31802e744b
  5. American Psychiatric Association, 2000, Diagnostic and Statistical Manual of Mental Disorders 4th Edition, Text Revision, DSM-IV-TR
  6. Amsterdam, 2016, Step-wise loss of antidepressant effectiveness with repeated antidepressant trials in bipolar II depression, Bipolar Disord, 18, 563, 10.1111/bdi.12442 · DOI
  7. Amsterdam, 2016, Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate, Br J Psychiatry, 208, 359, 10.1192/bjp.bp.115.169375 · DOI · Paper page
  8. Anand, 2012, Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial, Bipolar Disord, 14, 64, 10.1111/j.1399-5618.2011.00971.x · DOI · Paper page
  9. Aronson, 1989, Clonazepam treatment of five lithium-refractory patients with bipolar disorder, Am J Psychiatry, 146, 77, 10.1176/ajp.146.1.77 · DOI
  10. Baek, 2014, Pattern of pharmacotherapy by episode types for patients with bipolar disorders and its concordance with treatment guidelines, J Clin Psychopharmacol, 34, 577, 10.1097/JCP.0000000000000175 · DOI
  11. Ball, 2006, A randomized controlled trial of cognitive therapy for bipolar disorder: focus on long-term change, J Clin Psychiatry, 67, 277, 10.4088/JCP.v67n0215 · DOI · Paper page
  12. Barton, 1987, Verapamil in treatment-resistant mania: an open trial, J Clin Psychopharmacol, 7, 101, 10.1097/00004714-198704000-00011 · DOI
  13. Bauer, 2017, The Link between refractoriness and neuroprogression in treatment-resistant bipolar disorder, Mod Trends Pharmacopsychiatry, 31, 10, 10.1159/000470803 · DOI
  14. Bauer, 1994, Refractoriness induced by lithium discontinuation despite adequate serum lithium levels, Am J Psychiatry, 151, 1522, 10.1176/ajp.151.10.1522 · DOI
  15. Bauer, 1999, Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double-blind study, J Clin Psychopharmacol, 19, 164, 10.1097/00004714-199904000-00012 · DOI · Paper page
  16. Bauer, 2002, Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders, Neuropsychopharmacology, 27, 620
  17. Bauer, 2016, Levothyroxine effects on depressive symptoms and limbic glucose metabolism in bipolar disorder: a randomized, placebo-controlled positron emission tomography study, Mol Psychiatry, 21, 229, 10.1038/mp.2014.186 · DOI
  18. Bauer, 1990, Rapid cycling bipolar affective disorder, Archives of General Psychiatry, 47, 435, 10.1001/archpsyc.1990.01810170035006 · DOI · Paper page
  19. Bauer, 1990, Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study, Arch Gen Psychiatry, 47, 435, 10.1001/archpsyc.1990.01810170035006 · DOI · Paper page
  20. Behzadi, 2009, Folic acid efficacy as an alternative drug added to sodium valproate in the treatment of acute phase of mania in bipolar disorder: a double-blind randomized controlled trial, Acta Psychiatr Scand, 120, 441, 10.1111/j.1600-0447.2009.01368.x · DOI
  21. Benedetti, 2010, Augmentation of clozapine with aripiprazole in severe psychotic bipolar and schizoaffective disorders: a pilot study, Clinical practice and epidemiology in mental health: CP & EMH, 6, 30, 10.2174/1745017901006010030 · doi:10.2174/1745017901006010030
  22. Berk, 2011, Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention, Bipolar Disord, 13, 87, 10.1111/j.1399-5618.2011.00889.x · DOI · Paper page
  23. Berk, 2019, A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo, BMC Med, 17, 18, 10.1186/s12916-019-1257-1 · DOI · Paper page
  24. Berk, 2019, Correction to: a randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo, BMC Med, 17, 35, 10.1186/s12916-019-1280-2 · DOI
  25. Bersudsky, 2010, Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial, Bipolar Disord, 12, 376, 10.1111/j.1399-5618.2010.00828.x · DOI
  26. Berwaerts, 2011, Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study, J Affect Disord, 129, 252, 10.1016/j.jad.2010.09.011 · DOI
  27. Bjørklund, 2016, Trends in the psychopharmacological treatment of bipolar disorder: a nationwide register-based study, Acta Neuropsychiatr, 28, 75, 10.1017/neu.2015.52 · DOI
  28. Bobo, 2010, Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder, Expert Rev Neurother, 10, 1637, 10.1586/ern.10.143 · DOI · Paper page
  29. Bobo, 2016, Ketamine for treatment-resistant unipolar and bipolar major depression: critical review and implications for clinical practice, Depress Anxiety, 33, 698, 10.1002/da.22505 · DOI
  30. Bocchetta, 1993, A double-blind study of L-sulpiride versus amitriptyline in lithium-maintained bipolar depressives, Acta Psychiatr Scand, 88, 434, 10.1111/j.1600-0447.1993.tb03487.x · DOI · Paper page
  31. Bowden, 1999, The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder, Biol Psychiatry, 45, 953, 10.1016/S0006-3223(99)00013-X · DOI
  32. Burdick, 2012, Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction, J Clin Psychiatry, 73, 103, 10.4088/JCP.11m07299 · DOI
  33. Caddy, 2014, Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy, Ther Adv Psychopharmacol, 4, 75, 10.1177/2045125313507739 · DOI
  34. Calabrese, 1996, Clozapine for treatment-refractory mania, Am J Psychiatry, 153, 759, 10.1176/ajp.153.6.759 · DOI · Paper page
  35. Calabrese, 1999, Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder, Am J Psychiatry, 156, 1019, 10.1176/ajp.156.7.1019 · DOI · Paper page
  36. Calabrese, 2001, A pilot study of topiramate as monotherapy in the treatment of acute mania, J Clin Psychopharmacol, 21, 340, 10.1097/00004714-200106000-00015 · DOI
  37. Calabrese, 2010, Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study, J Clin Psychiatry, 71, 1363, 10.4088/JCP.09m05900gry · DOI
  38. Calabrese, 2014, Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial, J Clin Psychiatry, 75, 1054, 10.4088/JCP.13m08951 · DOI
  39. Cardoso, 2015, Biological rhythm and bipolar disorder: twelve-month follow-up of a randomized clinical trial, J Nerv Ment Dis, 203, 792, 10.1097/NMD.0000000000000369 · DOI
  40. Chen, 2011, Safety and efficacy of olanzapine monotherapy in treatment-resistant bipolar mania: a 12-week open-label study, Hum Psychopharmacol, 26, 588, 10.1002/hup.1249 · DOI
  41. Chen, 2013, A randomized, 4-week double-blind placebo control study on the efficacy of donepezil augmentation of lithium for treatment of acute mania, Neuropsychiatr Dis Treat, 9, 839, 10.2147/NDT.S40503 · DOI
  42. Chengappa, 1999, Topiramate as add-on treatment for patients with bipolar mania, Bipolar Disord, 1, 42, 10.1034/j.1399-5618.1999.10111.x · DOI
  43. Chengappa, 2000, Inositol as an add-on treatment for bipolar depression, Bipolar Disord, 2, 47, 10.1034/j.1399-5618.2000.020107.x · DOI
  44. Chiu, 2005, Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder, J Clin Psychiatry, 66, 1613, 10.4088/JCP.v66n1219b · DOI · Paper page
  45. Ciapparelli, 2000, Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study, J Clin Psychiatry, 61, 329, 10.4088/JCP.v61n0502 · DOI
  46. Ciapparelli, 2003, Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study, J Clin Psychiatry, 64, 451, 10.4088/JCP.v64n0416 · DOI
  47. Ciappolino, 2017, The role of n-3 polyunsaturated fatty acids (n-3PUFAs) in affective disorders, J Affect Disord, 224, 32, 10.1016/j.jad.2016.12.034 · DOI
  48. Citrome, 2010, Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults, Expert Rev Neurother, 10, 1031, 10.1586/ern.10.66 · DOI
  49. Cole, 1993, Patterns of treatment resistance in bipolar affective disorder, Acta Psychiatr Scand, 88, 121, 10.1111/j.1600-0447.1993.tb03424.x · DOI
  50. Colom, 2003, A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission, Arch Gen Psychiatry, 60, 402, 10.1001/archpsyc.60.4.402 · DOI · Paper page
  51. Colom, 2009, Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial, Br J Psychiatry, 194, 260, 10.1192/bjp.bp.107.040485 · DOI · Paper page
  52. Colom, 2010, Has number of previous episodes any effect on response to group psychoeducation in bipolar patients? A 5-year follow-up post hoc analysis, Acta Neuropsychiatr, 22, 50, 10.1111/j.1601-5215.2010.00450.x · DOI
  53. da Costa, 2016, Refractory bipolar disorder and neuroprogression, Prog Neuropsychopharmacol Biol Psychiatry, 70, 103, 10.1016/j.pnpbp.2015.09.005 · DOI
  54. Dauphinais, 2012, Controlled trial of safety and efficacy of bright light therapy vs. negative air ions in patients with bipolar depression, Psychiatry Res, 196, 57, 10.1016/j.psychres.2012.01.015 · DOI · Paper page
  55. de Barros Pellegrinelli, 2013, Efficacy of psychoeducation on symptomatic and functional recovery in bipolar disorder, Acta Psychiatr Scand, 127, 153, 10.1111/acps.12007 · DOI · Paper page
  56. De Beaurepaire, 1992, Treatment of neuroleptic-resistant mania and schizoaffective disorders, Am J Psychiatry, 149, 1614, 10.1176/ajp.149.11.1614 · doi:10.1176/ajp.149.11.1614
  57. Dell’Osso, 2013, Assessing efficacy/effectiveness and safety/tolerability profiles of adjunctive pramipexole in bipolar depression: acute versus long-term data, Int Clin Psychopharmacol, 28, 297, 10.1097/YIC.0b013e3283639015 · DOI
  58. Dell’Osso, 2009, Augmentative repetitive navigated transcranial magnetic stimulation (rTMS) in drug-resistant bipolar depression, Bipolar Disord, 11, 76, 10.1111/j.1399-5618.2008.00651.x · DOI
  59. Denicoff, 1997, Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder, Am J Psychiatry, 154, 1456, 10.1176/ajp.154.10.1456 · DOI
  60. D’Urso, 2017, Clinical predictors of acute response to transcranial direct current stimulation (tDCS) in major depression, J Affect Disord, 219, 25, 10.1016/j.jad.2017.05.019 · DOI
  61. Eden Evins, 2006, A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania, Bipolar Disord, 8, 75, 10.1111/j.1399-5618.2006.00243.x · DOI
  62. Erfurth, 2002, Bupropion as add-on strategy in difficult-to-treat bipolar depressive patients, Neuropsychobiology, 45 (Suppl 1), 33, 10.1159/000049259 · DOI
  63. Esan, 2017, Bipolar I disorder in remission vs. schizophrenia in remission: is there a difference in burden?, Compr Psychiatry, 72, 130, 10.1016/j.comppsych.2016.10.009 · DOI
  64. Fan, 2012, Allopurinol augmentation in the outpatient treatment of bipolar mania: a pilot study, Bipolar Disord, 14, 206, 10.1111/j.1399-5618.2012.01001.x · DOI
  65. Fitzgerald, 2016, A negative double-blind controlled trial of sequential bilateral rTMS in the treatment of bipolar depression, J Affect Disord, 198, 158, 10.1016/j.jad.2016.03.052 · DOI
  66. Fond, 2014, Ketamine’s effectiveness in unipolar versus bipolar depression, Psychopharmacology (Berl), 231, 4417, 10.1007/s00213-014-3773-1 · DOI
  67. Fountoulakis, 2010, An update of evidence-based treatment of bipolar depression: where do we stand?, Curr Opin Psychiatry, 23, 19, 10.1097/YCO.0b013e328333e132 · DOI
  68. Fountoulakis, 2012, Refractoriness in bipolar disorder: definitions and evidence-based treatment, CNS Neurosci Ther, 18, 227, 10.1111/j.1755-5949.2011.00259.x · DOI · Paper page
  69. Fountoulakis, 2007, A seven- year follow-up of an extremely refractory bipolar I patient, CNS Spectr, 12, 733, 10.1017/S109285290001539X · doi:10.1017/s109285290001539x
  70. Fountoulakis, 2008, Ultra short manic-like episodes after antidepressant augmentation with modafinil, Prog Neuropsychopharmacol Biol Psychiatry, 32, 891, 10.1016/j.pnpbp.2007.11.006 · DOI
  71. Fountoulakis, 2017, The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 2: review, grading of the evidence, and a precise algorithm, Int J Neuropsychopharmacol, 20, 121
  72. Fountoulakis, 2017, The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines, Int J Neuropsychopharmacol, 20, 180
  73. Fountoulakis, 2017, The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), part 4: unmet needs in the treatment of bipolar disorder and recommendations for future research, Int J Neuropsychopharmacol, 20, 196
  74. Fountoulakis, 2017, The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), part 1: background and methods of the development of guidelines, Int J Neuropsychopharmacol, 20, 98
  75. Fountoulakis, 2012, Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry, Eur Arch Psychiatry Clin Neurosci, 262, 1, 10.1007/s00406-012-0323-x · DOI
  76. Fountoulakis, 2015, Report of the WPA section of pharmacopsychiatry on the relationship of antiepileptic drugs with suicidality in epilepsy, Int J Psychiatry Clin Pract, 19, 158, 10.3109/13651501.2014.1000930 · DOI
  77. Frangou, 2007, Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder, J Psychopharmacol, 21, 435, 10.1177/0269881106067787 · DOI
  78. Fries, 2012, Staging and neuroprogression in bipolar disorder, Curr Psychiatry Rep, 14, 667, 10.1007/s11920-012-0319-2 · DOI
  79. Frye, 2007, A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression, Am J Psychiatry, 164, 1242, 10.1176/appi.ajp.2007.06060981 · DOI · Paper page
  80. Gabriel, 2007, Adjunctive topiramate treatment in refractory obese bipolar patients: a descriptive open label study, Eat Weight Disord, 12, 48, 10.1007/BF03327772 · DOI
  81. Gajwani, 2009, Treatment-refractory bipolar disorder: classification to aid in clinical management, Expert Opin Pharmacother, 10, 1907, 10.1517/14656560903064170 · DOI
  82. Galling, 2015, Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis, Expert Opin Drug Saf, 14, 1181, 10.1517/14740338.2015.1053457 · DOI
  83. Geddes, 2002, BALANCE: a large simple trial of maintenance treatment for bipolar disorder, World Psychiatry, 1, 48
  84. Geddes, 2016, Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial, Lancet Psychiatry, 3, 31, 10.1016/S2215-0366(15)00450-2 · DOI · Paper page
  85. Ghaemi, 2004, Strategies for preventing the recurrence of bipolar disorder, J Clin Psychiatry, 65 (Suppl 10), 16
  86. Ghanizadeh, 2014, Lovastatin as an adjuvant to lithium for treating manic phase of bipolar disorder: a 4-week, randomized, double-blind, placebo-controlled clinical trial, Depress Res Treat, 2014, 730505
  87. Gijsman, 2004, Antidepressants for bipolar depression: a systematic review of randomized, controlled trials, Am J Psychiatry, 161, 1537, 10.1176/appi.ajp.161.9.1537 · DOI · Paper page
  88. Gitlin, 2006, Treatment-resistant bipolar disorder, Mol Psychiatry, 11, 227, 10.1038/sj.mp.4001793 · DOI · Paper page
  89. Gitlin, 2001, Treatment-resistant bipolar disorder, Bull Menninger Clin, 65, 26, 10.1521/bumc.65.1.26.18709 · DOI
  90. Goldberg, 2004, Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression, Am J Psychiatry, 161, 564, 10.1176/appi.ajp.161.3.564 · DOI · Paper page
  91. González-Isasi, 2010, Long-term efficacy of a psychological intervention program for patients with refractory bipolar disorder: a pilot study, Psychiatry Res, 176, 161, 10.1016/j.psychres.2008.06.047 · DOI
  92. González-Isasi, 2012, Predictors of good outcome in patients with refractory bipolar disorder after a drug or a drug and cognitive-behavioral treatment, Compr Psychiatry, 53, 224, 10.1016/j.comppsych.2011.05.001 · DOI
  93. González Isasi, 2014, Psychoeducation and cognitive-behavioral therapy for patients with refractory bipolar disorder: a 5-year controlled clinical trial, Eur Psychiatry, 29, 134, 10.1016/j.eurpsy.2012.11.002 · DOI · Paper page
  94. Green, 2000, Clozapine in the treatment of refractory psychotic mania, Am J Psychiatry, 157, 982, 10.1176/appi.ajp.157.6.982 · DOI
  95. Harel, 2011, H-coil repetitive transcranial magnetic stimulation for the treatment of bipolar depression: an add-on, safety and feasibility study, World J Biol Psychiatry, 12, 119, 10.3109/15622975.2010.510893 · DOI · Paper page
  96. Harvey, 2015, Treating insomnia improves mood state, sleep, and functioning in bipolar disorder: a pilot randomized controlled trial, J Consult Clin Psychol, 83, 564, 10.1037/a0038655 · DOI · Paper page
  97. Hidalgo-Mazzei, 2019, Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition, Br J Psychiatry, 214, 27, 10.1192/bjp.2018.257 · DOI
  98. Houston, 2006, Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex, J Clin Psychiatry, 67, 1246, 10.4088/JCP.v67n0811 · DOI
  99. Houston, 2009, Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study, J Clin Psychiatry, 70, 1540, 10.4088/JCP.08m04895yel · DOI
  100. Hui Poon, 2015, Pharmacological approaches for treatment-resistant bipolar disorder, Curr Neuropharmacol, 13, 592, 10.2174/1570159X13666150630171954 · DOI
  101. Investigators B, collaborators, 2010, Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial, Lancet, 375, 385, 10.1016/S0140-6736(09)61828-6 · DOI · Paper page
  102. Ionescu, 2015, A single infusion of ketamine improves depression scores in patients with anxious bipolar depression, Bipolar Disord, 17, 438, 10.1111/bdi.12277 · DOI
  103. Isasi, 2010, How effective is a psychological intervention program for patients with refractory bipolar disorder? A randomized controlled trial, J Affect Disord, 126, 80, 10.1016/j.jad.2010.03.026 · DOI
  104. Jahangard, 2014, In a double-blind, randomized and placebo-controlled trial, adjuvant allopurinol improved symptoms of mania in in-patients suffering from bipolar disorder, Eur Neuropsychopharmacol, 24, 1210, 10.1016/j.euroneuro.2014.05.013 · DOI
  105. Juruena, 2009, Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial, Prog Neuropsychopharmacol Biol Psychiatry, 33, 94, 10.1016/j.pnpbp.2008.10.012 · DOI
  106. Kagawa, 2014, Relationship between plasma concentrations of lamotrigine and its early therapeutic effect of lamotrigine augmentation therapy in treatment-resistant depressive disorder, Ther Drug Monit, 36, 730, 10.1097/FTD.0000000000000088 · DOI
  107. Keck, 2001, Definition, evaluation, and management of treatment refractory mania, Psychopharmacol Bull, 35, 130
  108. Keller, 1992, Subsyndromal symptoms in bipolar disorder. A comparison of standard and low serum levels of lithium, Arch Gen Psychiatry, 49, 371, 10.1001/archpsyc.1992.01820050035005 · DOI · Paper page
  109. Kessing, 2016, Nationwide and population-based prescription patterns in bipolar disorder, Bipolar Disord, 18, 174, 10.1111/bdi.12371 · DOI
  110. Kessler, 2013, Neurocognitive profiles in treatment-resistant bipolar I and bipolar II disorder depression, BMC Psychiatry, 13, 105, 10.1186/1471-244X-13-105 · DOI
  111. Ketter, 2006, Adjunctive aripiprazole in treatment-resistant bipolar depression, Ann Clin Psychiatry, 18, 169, 10.1080/10401230600801176 · DOI · Paper page
  112. Ketter, 2015, Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder, J Affect Disord, 181, 87, 10.1016/j.jad.2015.04.012 · DOI
  113. Kimmel, 1994, Clozapine in treatment-refractory mood disorders, J Clin Psychiatry, 55, 91
  114. Koukopoulos, 1995, The long term prophylaxis of affective disorders, Adv Biochem Psychopharmacol, 49, 127
  115. Koukopoulos, 2010, Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorder, Bipolar Disord, 12, 348, 10.1111/j.1399-5618.2010.00803.x · DOI
  116. Kramlinger, 1989, Adding lithium carbonate to carbamazepine: antimanic efficacy in treatment-resistant mania, Acta Psychiatr Scand, 79, 378, 10.1111/j.1600-0447.1989.tb10273.x · DOI
  117. Kraus, 2017, Administration of ketamine for unipolar and bipolar depression, Int J Psychiatry Clin Pract, 21, 2, 10.1080/13651501.2016.1254802 · DOI
  118. Kusumakar, 1997, An open study of lamotrigine in refractory bipolar depression, Psychiatry Res, 72, 145, 10.1016/S0165-1781(97)00082-6 · DOI
  119. Lally, 2014, Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression, Transl Psychiatry, 4, e469, 10.1038/tp.2014.105 · DOI · Paper page
  120. Lattanzi, 2002, Pramipexole in treatment-resistant depression: a 16-week naturalistic study, Bipolar Disord, 4, 307, 10.1034/j.1399-5618.2002.01171.x · DOI · Paper page
  121. Lee, 2014, The effects of add-on low-dose memantine on cytokine levels in bipolar II depression: a 12-week double-blind, randomized controlled trial, J Clin Psychopharmacol, 34, 337, 10.1097/JCP.0000000000000109 · DOI
  122. Lee, 2014, Genotype variant associated with add-on memantine in bipolar II disorder, Int J Neuropsychopharmacol, 17, 189, 10.1017/S1461145713000825 · DOI
  123. Li, 2015, Clozapine for treatment-resistant bipolar disorder: a systematic review, Bipolar Disord, 17, 235, 10.1111/bdi.12272 · DOI
  124. Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, Bmj, 339, b2700, 10.1136/bmj.b2700 · DOI · Paper page
  125. Lipsman, 2010, Neurosurgical treatment of bipolar depression: defining treatment resistance and identifying surgical targets, Bipolar Disord, 12, 691, 10.1111/j.1399-5618.2010.00868.x · DOI
  126. Liu, 2017, Efficacy and safety of long-term antidepressant treatment for bipolar disorders - A meta-analysis of randomized controlled trials, J Affect Disord, 223, 41, 10.1016/j.jad.2017.07.023 · DOI
  127. Lobban, 2010, Enhanced relapse prevention for bipolar disorder by community mental health teams: cluster feasibility randomised trial, Br J Psychiatry, 196, 59, 10.1192/bjp.bp.109.065524 · DOI · Paper page
  128. Loebel, 2014, Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study, Am J Psychiatry, 171, 169, 10.1176/appi.ajp.2013.13070985 · DOI · Paper page
  129. Loo, 2011, Physical treatments for bipolar disorder: a review of electroconvulsive therapy, stereotactic surgery and other brain stimulation techniques, J Affect Disord, 132, 1, 10.1016/j.jad.2010.08.017 · DOI
  130. van der Loos, 2009, Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial, J Clin Psychiatry, 70, 223, 10.4088/JCP.08m04152 · DOI · Paper page
  131. van der Loos, 2010, Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine, Acta Psychiatr Scand, 122, 246, 10.1111/j.1600-0447.2009.01537.x · DOI
  132. van der Loos, 2011, Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design, Bipolar Disord, 13, 111, 10.1111/j.1399-5618.2011.00887.x · DOI
  133. Lykouras, 2004, Adjunctive topiramate in the maintenance treatment of bipolar disorders: an open-label study, Curr Med Res Opin, 20, 843, 10.1185/030079904125003665 · DOI
  134. Macfadden, 2009, A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently, Bipolar Disord, 11, 827, 10.1111/j.1399-5618.2009.00761.x · DOI · Paper page
  135. Machado-Vieira, 2008, A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania, J Clin Psychiatry, 69, 1237, 10.4088/JCP.v69n0806 · DOI · Paper page
  136. Magalhaes, 2011, N-acetylcysteine for major depressive episodes in bipolar disorder, Braz J Psychiatry, 33, 374, 10.1590/S1516-44462011000400011 · DOI
  137. Magalhaes, 2011, N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebocontrolled trial, J Affect Disord, 129, 317, 10.1016/j.jad.2010.08.001 · DOI
  138. Mahableshwarkar, 2017, Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: a phase 3, randomized controlled trial, J Affect Disord, 221, 275, 10.1016/j.jad.2017.06.044 · DOI
  139. Maj, 1995, Nonresponse to reinstituted lithium prophylaxis in previously responsive bipolar patients: prevalence and predictors, Am J Psychiatry, 152, 1810, 10.1176/ajp.152.12.1810 · DOI · Paper page
  140. Manning, 2005, Burden of illness in bipolar depression, Prim Care Companion J Clin Psychiatry, 7, 259, 10.4088/PCC.v07n0601 · DOI
  141. Marangell, 2008, A 1-year pilot study of vagus nerve stimulation in treatment-resistant rapid-cycling bipolar disorder, J Clin Psychiatry, 69, 183, 10.4088/JCP.v69n0203 · DOI
  142. Marcus, 2011, Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study, Bipolar Disord, 13, 133, 10.1111/j.1399-5618.2011.00898.x · DOI
  143. van der Markt, 2019, Testing a clinical staging model for bipolar disorder using longitudinal life chart data, Bipolar Disord, 21, 228, 10.1111/bdi.12727 · DOI
  144. McElroy, 1991, Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia, J Clin Psychiatry, 52, 411
  145. McElroy, 1997, A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder, Ann Clin Psychiatry, 9, 99, 10.3109/10401239709147781 · DOI
  146. McElroy, 1998, Olanzapine in treatment-resistant bipolar disorder, J Affect Disord, 49, 119, 10.1016/S0165-0327(98)00002-0 · DOI
  147. McElroy, 2000, Open-label adjunctive topiramate in the treatment of bipolar disorders, Biol Psychiatry, 47, 1025, 10.1016/S0006-3223(99)00316-9 · DOI · Paper page
  148. McElroy, 2011, A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance, Int Clin Psychopharmacol, 26, 48, 10.1097/YIC.0b013e3283400d35 · DOI
  149. McElroy, 2015, Adjunctive lisdexamfetamine in bipolar depression: a preliminary randomized, placebo-controlled trial, Int Clin Psychopharmacol, 30, 6, 10.1097/YIC.0000000000000051 · DOI
  150. Medda, 2009, Response to ECT in bipolar I, bipolar II and unipolar depression, J Affect Disord, 118, 55, 10.1016/j.jad.2009.01.014 · DOI
  151. Medda, 2010, Comparative response to electroconvulsive therapy in medication-resistant bipolar I patients with depression and mixed state, J Ect, 26, 82, 10.1097/YCT.0b013e3181b00f1e · DOI
  152. Medda, 2015, Electroconvulsive therapy in 197 patients with a severe, drug-resistant bipolar mixed state: treatment outcome and predictors of response, J Clin Psychiatry, 76, 1168, 10.4088/JCP.14m09181 · DOI
  153. Mendlewicz, 2010, Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study, Int Clin Psychopharmacol, 25, 297, 10.1097/YIC.0b013e32833c4ceb · DOI
  154. Meyer, 2012, Cognitive behaviour therapy and supportive therapy for bipolar disorders: relapse rates for treatment period and 2-year follow-up, Psychol Med, 42, 1429, 10.1017/S0033291711002522 · DOI · Paper page
  155. Miller, 1991, Prediction of treatment response in bipolar, manic disorder, J Affect Disord, 21, 75, 10.1016/0165-0327(91)90052-T · doi:10.1016/0165-0327(91)90052-t
  156. Mishory, 2000, Phenytoin as an antimanic anticonvulsant: a controlled study, Am J Psychiatry, 157, 463, 10.1176/appi.ajp.157.3.463 · DOI
  157. Mishory, 2003, Prophylactic effect of phenytoin in bipolar disorder: a controlled study, Bipolar Disord, 5, 464, 10.1046/j.1399-5618.2003.00070.x · DOI
  158. Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, Bmj, 339, b2535, 10.1136/bmj.b2535 · DOI · Paper page
  159. Mukai, 2014, A meta-analysis of inositol for depression and anxiety disorders, Hum Psychopharmacol, 29, 55, 10.1002/hup.2369 · DOI · Paper page
  160. Mukherjee, 1988, Unilateral ECT in the treatment of manic episodes, Convuls Ther, 4, 74
  161. Murphy, 2012, Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder: a double-blind, randomized add-on clinical trial, J Clin Psychopharmacol, 32, 699, 10.1097/JCP.0b013e318266854c · DOI
  162. Murphy, 2014, Oral SAMe in persistent treatment-refractory bipolar depression: a double-blind, randomized clinical trial, J Clin Psychopharmacol, 34, 413, 10.1097/JCP.0000000000000064 · DOI
  163. Murray, 1994, Lithium maintenance therapy for bipolar I patients: possible refractoriness to reinstitution after discontinuation, Psychol Rep, 74, 355, 10.2466/pr0.1994.74.2.355 · DOI
  164. Nemeroff, 2001, Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression, Am J Psychiatry, 158, 906, 10.1176/appi.ajp.158.6.906 · DOI · Paper page
  165. Nierenberg, 2006, Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone, Am J Psychiatry, 163, 210, 10.1176/appi.ajp.163.2.210 · DOI · Paper page
  166. Nivoli, 2011, Gender differences in a cohort study of 604 bipolar patients: the role of predominant polarity, J Affect Disord, 133, 443, 10.1016/j.jad.2011.04.055 · DOI · Paper page
  167. Norris, 2013, A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder, J Affect Disord, 144, 141, 10.1016/j.jad.2012.06.023 · DOI
  168. Nuñez, 2018, Psychopathological and sociodemographic features in treatment-resistant unipolar depression versus bipolar depression: a comparative study, BMC Psychiatry, 18, 68, 10.1186/s12888-018-1641-y · DOI
  169. Obrocea, 2002, Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders, Biol Psychiatry, 51, 253, 10.1016/S0006-3223(01)01206-9 · DOI
  170. Ostacher, 2014, When positive isn’t positive: the hopes and disappointments of clinical trials, J Clin Psychiatry, 75, e1186, 10.4088/JCP.14com09427 · DOI
  171. Pacchiarotti, 2009, Treatment-resistant bipolar depression: towards a new definition, Acta Psychiatr Scand, 120, 429, 10.1111/j.1600-0447.2009.01471.x · DOI
  172. Pae, 2012, Achieving and sustaining remission in bipolar I disorder with ziprasidone: a post hoc analysis of a 24-week, double-blind, placebo-controlled study, Clin Drug Investig, 32, 747, 10.1007/s40261-012-0009-1 · DOI
  173. Pallanti, 2014, rTMS in resistant mixed states: an exploratory study, J Affect Disord, 157, 66, 10.1016/j.jad.2013.12.024 · DOI
  174. Pande, 2000, Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group, Bipolar Disord, 2, 249, 10.1034/j.1399-5618.2000.20305.x · DOI · Paper page
  175. Parikh, 2010, Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), Can J Psychiatry, 55, 136, 10.1177/070674371005500304 · DOI
  176. Parker, 2017, Clinical characteristics associated with treatment-resistant bipolar disorder, J Nerv Ment Dis, 205, 188, 10.1097/NMD.0000000000000517 · DOI
  177. Parsaik, 2015, Efficacy of ketamine in bipolar depression: systematic review and meta-analysis, J Psychiatr Pract, 21, 427, 10.1097/PRA.0000000000000106 · DOI
  178. Passos, 2017, Should bipolar disorder treatment be modified depending on staging?, Expert Rev Neurother, 17, 93, 10.1080/14737175.2017.1268532 · DOI
  179. Patkar, 2015, A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder, J Clin Psychopharmacol, 35, 319, 10.1097/JCP.0000000000000323 · DOI
  180. Pazzaglia, 1993, Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation, Psychiatry Res, 49, 257, 10.1016/0165-1781(93)90066-P · DOI
  181. Pazzaglia, 1998, Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness, J Clin Psychopharmacol, 18, 404, 10.1097/00004714-199810000-00009 · DOI
  182. Perry, 1999, Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment, Bmj, 318, 149, 10.1136/bmj.318.7177.149 · DOI · Paper page
  183. Perugi, 1999, Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states, Pharmacopsychiatry, 32, 136, 10.1055/s-2007-979219 · DOI · Paper page
  184. Perugi, 2012, Episode length and mixed features as predictors of ECT nonresponse in patients with medication-resistant major depression, Brain Stimul, 5, 18, 10.1016/j.brs.2011.02.003 · DOI
  185. Pilhatsch, 2010, Comparison of paroxetine and amitriptyline as adjunct to lithium maintenance therapy in bipolar depression: a reanalysis of a randomized, double-blind study, J Affect Disord, 126, 453, 10.1016/j.jad.2010.04.025 · DOI
  186. Poleszczyk, 2018, Are there clinical and neurophysiologic predictive factors for a positive response to HF-rTMS in patients with treatment-resistant depression?, Psychiatry Res, 264, 175, 10.1016/j.psychres.2018.03.084 · DOI
  187. Poon, 2012, Evidence-based options for treatment-resistant adult bipolar disorder patients, Bipolar Disord, 14, 573, 10.1111/j.1399-5618.2012.01042.x · DOI
  188. Pope, 1991, Valproatereatment of Acute Mania, Arch Gen Psychiatry, 48, 62, 10.1001/archpsyc.1991.01810250064008 · DOI · Paper page
  189. Pope, 1991, Valproate in the treatment of acute mania. A placebo-controlled study, Arch Gen Psychiatry, 48, 62, 10.1001/archpsyc.1991.01810250064008 · DOI · Paper page
  190. Popovic, 2012, Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder, Eur Neuropsychopharmacol, 22, 339, 10.1016/j.euroneuro.2011.09.008 · DOI · Paper page
  191. Popovic, 2013, Polarity index of psychological interventions in maintenance treatment of bipolar disorder, Psychother Psychosom, 82, 292, 10.1159/000348447 · DOI · Paper page
  192. Popovic, 2014, Clinical implications of predominant polarity and the polarity index in bipolar disorder: a naturalistic study, Acta Psychiatr Scand, 129, 366, 10.1111/acps.12179 · DOI
  193. Post, 2012, Acquired lithium resistance revisited: discontinuation-induced refractoriness versus tolerance, J Affect Disord, 140, 6, 10.1016/j.jad.2011.09.021 · DOI
  194. Post, 2005, Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder, J Clin Psychiatry, 66, 370, 10.4088/JCP.v66n0314 · DOI
  195. Post, 2001, Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers, Bipolar Disord, 3, 259, 10.1034/j.1399-5618.2001.30505.x · doi:10.1034/j.1399-5618.2001.30505.x
  196. Post, 2008, Loss of previous responsiveness to lithium following its discontinuation and subsequent episode recurrence, 123
  197. Post, 1992, Lithium-discontinuation-induced refractoriness: preliminary observations, Am J Psychiatry, 149, 1727, 10.1176/ajp.149.12.1727 · DOI · Paper page
  198. Post, 1993, Lithium tolerance and discontinuation as pathways to refractoriness, 71
  199. Potter, 1982, Clorgyline. A new treatment for patients with refractory rapid-cycling disorder, Arch Gen Psychiatry, 39, 505, 10.1001/archpsyc.1982.04290050001001 · DOI
  200. Quante, 2010, Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study, Hum Psychopharmacol, 25, 126, 10.1002/hup.1096 · DOI

200 of 282 shown

Cited by

See all 77

Metadata

Authors
Fountoulakis, K. N., Yatham, L. N., Grunze, H., Vieta, E., Young, A. H., Blier, P., Tohen, M., Kasper, S., & Moeller, H. J.
Venue
International Journal of Neuropsychopharmacology
Published
2019-12-05
Volume
23
Issue
4
Pages
230-256
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2992518829
Cited by
77
References
68
FWCI
4.39
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder. https://app.cochat.ai/papers/10.1093/ijnp/pyz064
The paper
Fountoulakis, K. N., Yatham, L. N., Grunze, H., Vieta, E., Young, A. H., Blier, P., Tohen, M., Kasper, S., & Moeller, H. J. (2020). The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyz064

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.